Sophie Pierce will be the first person with cystic fibrosis to attempt a 3,200-mile row across the Atlantic Ocean, travelling ...

The funding of up to £500,000 is provided by LifeArc, a medical research charity, to support the development of Glox’s ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung ...

Before working together on Baldoni’s current legal disputes with Blake Lively, Justin Baldoni and his attorney, Bryan Freedman, clashed over copyright infringement claims ...

Bryan Freedman, now defending his client against Blake Lively’s accusations over 'It Ends With Us,' claimed Baldoni’s ...

Antibody Therapeutics Inc. has disclosed integrin receptor antagonists reported to be useful for the treatment of pulmonary fibrosis, renal fibrosis and hepatic fibrosis.